ReviewCurrent urology reports2018
Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.
Review in Current urology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- FKBP10 promotes M2 polarization of macrophage via MEK/ERK/CXCL8 axis and facilitates tumor progression in clear cell renal cell carcinoma.International journal of biological sciences · 2026Article
- Mutational landscape and clinical implications of VHL in clear cell renal cell carcinoma: a multi-dataset analysis of 1377.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Applicability of the regression approach for histological multi-class grading in clear cell renal cell carcinoma.Regenerative therapy · 2025Article
- HAGLR, A Long Non-coding RNA of Potential Tumor Suppressive Function in Clear Cell Renal Cell Carcinoma: Diagnostic and Prognostic Implications.Molecular biotechnology · 2024Article
- Circ_0061140 Potentiates Clear Cell Renal Cell Carcinoma Progression Via the MicroRNA-126-5p/ADAM9 Axis.Molecular biotechnology · 2024Article
- The success rate of small renal mass core needle biopsy and its impact on lowering benign resection rate.BMC urology · 2023Article
- The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma.Scientific reports · 2023Article
- Using the Synergy between HPLC-MS and MALDI-MS Imaging to Explore the Lipidomics of Clear Cell Renal Cell Carcinoma.Analytical chemistry · 2023Article
- Renal cell carcinoma with atypical metastases sites revealed by diabetes mellitus: A case report.Annals of medicine and surgery (2012) · 2022Article
- Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions.Cancers · 2022Review
- A Novel Cuproptosis-Related Prognostic Model and the Hub GeneJournal of oncology · 2022Article
- Review
- Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.Molecular oncology · 2021Article
- Natural history and growth kinetics of clear cell renal cell carcinoma in sporadic and von Hippel-Lindau disease.Translational andrology and urology · 2021Article
- Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets.Cancer immunology, immunotherapy : CII · 2020Article
- Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy.Journal of kidney cancer and VHL · 2020Article
- Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019Review
- Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report.Urology case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIntratumor heterogeneity is an inherent event in tumor development that is receiving much attention in the last years since it is responsible for most failures of current targeted therapies. The purpose of this review is to offer clinicians an updated insight of the multiple manifestations of a complex event that impacts significantly patient's life. RECENT
findingsClear cell renal cell carcinoma is the most common renal tumor and a paradigmatic example of a heterogeneous neoplasm. Next-generation sequencing has demonstrated that intratumor heterogeneity encompasses genetic, epigenetic, and microenvironmental variability. Currently accepted protocols of tumor sampling seem insufficient in unveiling intratumor heterogeneity with reliability and need to be updated. This variability challenges the precise morphological diagnosis, its molecular characterization, and the selection of optimal personalized therapies in clear cell renal cell carcinoma, a neoplasm traditionally considered chemo- and radio-resistant. We review the state of the art of the different approaches to intratumor heterogeneity in clear cell renal cell carcinomas, from the simple morphology to the most sophisticated massive sequencing tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.